VOLUME CV | SEP 2025

FDA Approves Subcutaneous Leqembi for Alzheimer’s

The U.S. Food and Drug Administration has approved Leqembi Iqlik, a subcutaneous version of lecanemab, for weekly maintenance after the 18-month intravenous (IV) phase.Leqembi Iqlik is a subcutaneous autoinjector that delivers treatment in about 15 seconds for U.S. patients…

Amir Khan

Amir is a Pakistani-Canadian neuroengineer in Toronto, developing brain-computer interfaces to enhance learning. As a volunteer author, he shares insights on how technology can amplify cognitive abilities, drawing from his diverse South Asian-Canadian perspective.

Read Full Article (External Site)

FDA Approves Subcutaneous Leqembi for Alzheimer’s

FDA Approves Gradual Dosing for Alzheimer’s Drug

FDA Approves Migraine Prevention Drug for Kids

FDA Approves Wearable Band for Kids’ Nasal Congestion